

# Phosphatidylcholine Synthesis Influences the Diacylglycerol Homeostasis Required for Sec14p-dependent Golgi Function and Cell Growth

Annette L. Henneberry, Thomas A. Lagace, Neale D. Ridgway, and Christopher R. McMaster\*

The Atlantic Research Centre, Departments of Pediatrics and Biochemistry and Molecular Biology, IWK Grace Health Centre, Dalhousie University, Halifax, Nova Scotia B3H 4H7, Canada

Submitted August 14, 2000; Revised October 25, 2000; Accepted December 21, 2000  
Monitoring Editor: Chris Kaiser

Phosphatidylcholine and phosphatidylethanolamine are the most abundant phospholipids in eukaryotic cells and thus have major roles in the formation and maintenance of vesicular membranes. In yeast, diacylglycerol accepts a phosphocholine moiety through a *CPT1*-derived cholinephosphotransferase activity to directly synthesize phosphatidylcholine. *EPT1*-derived activity can transfer either phosphocholine or phosphoethanolamine to diacylglycerol in vitro, but is currently believed to primarily synthesize phosphatidylethanolamine in vivo. In this study we report that *CPT1*- and *EPT1*-derived cholinephosphotransferase activities can significantly overlap in vivo such that *EPT1* can contribute to 60% of net phosphatidylcholine synthesis via the Kennedy pathway. Alterations in the level of diacylglycerol consumption through alterations in phosphatidylcholine synthesis directly correlated with the level of *SEC14*-dependent invertase secretion and affected cell viability. Administration of synthetic di8:0 diacylglycerol resulted in a partial rescue of cells from *SEC14*-mediated cell death. The addition of di8:0 diacylglycerol increased di8:0 diacylglycerol levels 20–40-fold over endogenous long-chain diacylglycerol levels. Di8:0 diacylglycerol did not alter endogenous phospholipid metabolic pathways, nor was it converted to di8:0 phosphatidic acid.


## INTRODUCTION

Phosphatidylethanolamine (PE) and phosphatidylcholine (PC) are the most abundant phospholipids present in eukaryotic cells, comprising ~25 and 50% of cell phospholipid mass, respectively (White, 1973; Paltauf *et al.*, 1992). As major membrane components PE and PC play important roles in the formation and maintenance of cellular, organellar, and vesicular membranes. PE and PC can each be synthesized through two pathways. PE can be synthesized via the decarboxylation of phosphatidylserine, or from ethanolamine to PE by Kennedy pathway enzymes (Kodaki and Yamashita, 1987; Vance, 1991; Clancey *et al.*, 1993; Cui *et al.*, 1993; Trotter *et al.*, 1993; Achleitner *et al.*, 1995; Trotter and Voelker, 1995). Hepatocytes and yeast cells have the capacity to methylate PE to PC, but all other eukaryotic cells described to date synthesize PC almost exclusively through the metabolism of choline by Kennedy pathway enzymes

(Weiss *et al.*, 1958; Vance, 1996). The Kennedy pathways for the synthesis of PE and PC phosphorylate either ethanolamine or choline to produce the phosphobase to which a CMP moiety is donated from CTP by a CTP:phosphobase cytidyltransferase to synthesize the CDP-base. In the final reaction of the pathway ethanolaminephosphotransferase transfers a phosphoethanolamine group from CDP-ethanolamine to diacylglycerol (DAG) to form PE, whereas cholinephosphotransferase catalyzes a similar reaction using CDP-choline as the phosphobase donor for the synthesis of PC (Figure 1) (Hjelmstad and Bell, 1990, 1991a,b; Hjelmstad *et al.*, 1994; McMaster and Bell, 1997a,b).

In the yeast *Saccharomyces cerevisiae*, *CPT1* and *EPT1* code for this organism's complement of cholinephosphotransferase and ethanolaminephosphotransferase activities. In vitro, the *CPT1* gene product acted almost exclusively as a cholinephosphotransferase, whereas the *EPT1* gene product catalyzed both cholinephosphotransferase and ethanolaminephosphotransferase reactions with similar efficiencies (McGee *et al.*, 1994; McMaster and Bell, 1994; Williams and McMaster, 1998). In vivo metabolic analysis of yeast disrupted for either the *CPT1* or *EPT1* genes revealed that the *CPT1* gene product synthesized 90–95% of Kennedy path-

\* Corresponding author. E-mail address: cmcmaste@is.dal.ca.  
Abbreviations used: CDP-DAG, CDP-diacylglycerol; DAG, diacylglycerol; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PI, phosphatidylinositol.



**Figure 1.** Synthesis and turnover of phosphatidylcholine. The Kennedy pathway for the synthesis of phosphatidylcholine and its turnover by phospholipase D are illustrated. Known yeast genes are in indicated in italics.

way-derived PC, with the *EPT1* product synthesizing the remaining 5–10% of PC and all of the Kennedy pathway-derived PE (McGee *et al.*, 1994; McMaster and Bell, 1994). Recent cloning of the human complement of cholinephosphotransferase and ethanolaminephosphotransferase enzymes revealed similar activity profiles. The human *CPT1* product could synthesize only PC *in vitro*, and in metabolic labeling experiments in yeast devoid of their endogenous activities due to genomic inactivation of the *CPT1* and *EPT1* loci, expression of human *CPT1* reconstituted PC synthesis, but not PE synthesis (Henneberry *et al.*, 2000). The human *CEPT1*-encoded activity synthesized PC and PE *in vitro*, and *in vivo* *CEPT1* reconstituted the synthesis of both PC and PE in yeast devoid of their endogenous cholinephosphotransferase and ethanolaminephosphotransferase activities (Henneberry and McMaster, 1999).

*SEC14* is an essential gene that codes for the major PC/phosphatidylinositol (PI) transfer protein in yeast (Aitken *et al.*, 1990; Bankaitis *et al.*, 1990; Cleves *et al.*, 1991). Ablation of *SEC14* function prevented Golgi-mediated protein transport and resulted in cell death (Cleves *et al.*, 1991; Kearns *et al.*, 1998; Phillips *et al.*, 1999). Utilization of a temperature-sensitive allele of *SEC14* (*sec14<sup>ts</sup>*) allowed for a search for mutations in other genes that would allow for survival in the face of a nonfunctional *SEC14* gene product. This screen resulted in the isolation of several *sec14<sup>ts</sup>* bypass suppressor genes (Cleves *et al.*, 1991). Three of the inactivated genes were found to code for each of the Kennedy pathway enzymes: choline kinase (*CKI1*), CTP:phosphocholine cytidyltransferase (*PCT1*), and cholinephosphotransferase (*CPT1*). Interestingly, none of the enzymes of the Kennedy pathway enzymes for the synthesis of PE were isolated during the screen, and intentional disruption of the yeast

*EKI1* (ethanolamine kinase) or *EPT1* gene products did not rescue cells from the requirement for a functional *SEC14* (Cleves *et al.*, 1991; Kim *et al.*, 1999). Hence, the cellular requirement for *SEC14* could only be bypassed by inactivating genes in the Kennedy pathway for the synthesis of PC, but not by inactivating genes specific for the synthesis of PE.

The ability of the *SEC14* bypass mutants to allow for cell survival in the absence of a functional *SEC14* gene product is currently postulated to be due to alterations in Golgi DAG pool sizes, with increased DAG allowing for growth in the absence of *SEC14*. However, both the *CPT1*- and *EPT1*-derived gene products directly consume DAG, and yet inactivation of *CPT1* bypassed the cellular requirement for *SEC14*, whereas inactivation of *EPT1* did not. This observation appears to be paradoxical with the DAG pool size hypothesis. The current study explores the metabolic partitioning between the Kennedy pathways for the synthesis of PC and PE in yeast, and the impact of endogenous DAG consumption and exogenous DAG administration on lipid metabolism and subsequent *SEC14*-mediated vesicle trafficking events.

## MATERIALS AND METHODS

### Materials

[methyl-<sup>14</sup>C]Choline chloride (52 mCi/mmol) and phosphorus 32 were purchased from DuPont/NEN (Boston, MA). [methyl-<sup>14</sup>C]CDP-choline was a product of American Radiolabeled Chemicals (St. Louis, MO). Lipids were products of Avanti Polar Lipids (Alabaster, AL) except for di8:0 phosphatidic acid, which was purchased from Sigma Chemical Co. (St. Louis, MO) Reagents for invertase assays, and glass beads for yeast disruption, were also obtained from Sigma Chemical Co. Thin-layer chromatography (TLC) plates were products of Whatman (Fisher, Nepean, Ont, Canada). All other reagents were of the highest quality commercially available.

### Yeast Strains and Media

Yeast strains used were CTY182 (a *ura3-52 his3-200 lys2-801 CPT1 EPT1*) (Cleves *et al.*, 1991), CTY1-1A (a *ura3-52 his3-200 lys2-801 sec14-1<sup>ts</sup>*) (23), CTY160 (a *ura3-52 his3-200 lys2-801 sec14-1<sup>ts</sup> cki1<sup>-</sup>*) (23), CTY468 (a *ura3-52 his3-200 lys2-801 sec14-1<sup>ts</sup> pct1::URA3*) (this study), CTY434 (a *ura3-52 ade2-101 leu2-3112 his4-519 sec14-1<sup>ts</sup> cpt1::LEU2*) (this study) (the kind gifts of Dr. Vyta Bankaitis, University of Alabama at Birmingham, Birmingham, AL), YPP649.7 (a *ura3 sec7<sup>ts</sup>*), YPP649.13 (a *ura3 sec13<sup>ts</sup>*), and YPP649.15 (a *ura3 sec15<sup>ts</sup>*) (the kind gifts of Dr. Gerald Johnston, Dalhousie University, Halifax, NS, Canada). Plasmids YEp352 (vector), pRH150 (*CPT1*), and pRH507 (*EPT1*) (Hjelmstad and Bell, 1990; Hjelmstad and Bell, 1991b) were propagated in *DH5 $\alpha$*  *Escherichia coli* and transformed into *S. cerevisiae* using lithium acetate with transformants selected on synthetic dextrose plates containing the appropriate nutritional supplements (Kaiser *et al.*, 1994). YPD medium was made as described (Kaiser *et al.*, 1994).

### Enzyme Assays

CTY434 (*sec14-1<sup>ts</sup> cpt1::LEU2 EPT1*) cells transformed with plasmids were grown to mid-log phase at 25°C in synthetic dextrose media containing the appropriate nutrients, and microsomal membranes prepared as described (McMaster and Bell, 1994). *CPT1*- and *EPT1*-derived cholinephosphotransferase activities were measured using the Triton X-100 mixed micelle protocol (Hjelmstad and Bell, 1991a).

## Metabolic Labeling

All metabolic labeling experiments were performed using yeast minimal media plus appropriate nutritional supplements. This media is choline and ethanolamine free unless supplemented exogenously as required for radiolabeling studies. Cells were radiolabeled with [ $^{14}$ C]choline at 25°C as previously described (McMaster and Bell, 1994). Inorganic phosphorus 32 (2.5 mCi) was added to 20 ml of early log phase CTY434 cells grown at 25°C, and at 4, 12, and 24 h a 5-ml aliquot was removed and centrifuged at 3000  $\times$  g for 5 min to pellet cells. Cells were washed twice with 5 ml of ice-cold water, resuspended in 1 ml of  $\text{CHCl}_3/\text{CH}_3\text{OH}$  (1/1, vol/vol), and transferred to 2-ml screw cap tubes containing 0.5 g of 0.5-mm glass beads. For the efficient extraction of di8:0 phosphatidic acid, perchloric acid was added to the extraction mixture at 0.7% (vol/vol). Cells were disrupted using a BioSpec bead beater for 1 min at 4°C. The beads were washed with 1.5 ml of  $\text{CHCl}_3/\text{CH}_3\text{OH}$  (2:1, vol/vol) and 0.5 ml of  $\text{CHCl}_3$  and 1.5 ml of  $\text{H}_2\text{O}$  were added to the combined homogenate. Tubes were vortexed and centrifuged at 2000  $\times$  g for 10 min to facilitate phase separation. The organic phase was washed once with an equal volume of 40%  $\text{CH}_3\text{OH}$  (vol/vol) and an aliquot of the organic phase was dried under nitrogen gas in the presence of phospholipid standards. Phospholipids were separated by two-dimensional TLC with  $\text{CHCl}_3/\text{CH}_3\text{COCH}_3/\text{CH}_3\text{OH}/\text{CH}_3\text{COOH}/\text{H}_2\text{O}$  (60:24:12:12:6, vol/vol) in the first dimension and  $\text{CHCl}_3/\text{CH}_3\text{OH}/\text{CH}_3\text{COOH}/\text{H}_2\text{O}$  (50:37.5:3.5:2, vol/vol) in the second dimension. Plates were exposed to x-ray film for 24–48 h and subsequently stained with iodine vapor. Iodine stained spots corresponding to the mobility of known standards were scraped into scintillation vials and counted.

## Diacylglycerol Pool Size Determination


CTY434 cells  $\pm$  plasmids were grown overnight at 25°C in synthetic dextrose media containing the appropriate nutrients. Optical densities were measured at 600 nm and each strain was diluted to  $A_{600}$  of 0.150. Cells were grown for 1 h at 25°C and the media was subsequently supplemented with di8:0 DAG to a final concentration of 200  $\mu\text{M}$ . Five-milliliter aliquots were removed at the indicated time points and lipids were extracted as described above. DAG levels were measured using the DAG kinase assay of Preiss *et al.* (1986), and lipids separated on by TLC using the solvent system  $\text{CHCl}_3/\text{CH}_3\text{OH}/\text{CH}_3\text{OOH}$  (65:15:5, vol/vol). This solvent system efficiently separated short-chain and long-chain phosphorylated DAG products.

## Suppression of *cpt1*<sup>-</sup>-mediated Bypass of *sec14*<sup>ts</sup>

CTY434 cells were grown overnight at 25°C in synthetic dextrose media containing the appropriate nutrients for plasmid maintenance. Optical densities were measured at 600 nm and each strain was diluted to the identical cell number. Serial dilutions of 1:10, 1:100, and 1:1000 were made in water and 1  $\mu\text{l}$  of each was spotted onto a synthetic dextrose plate containing the appropriate nutrients for plasmid maintenance  $\pm$  200  $\mu\text{M}$  di8:0 DAG (diacylglycerol stock was dried under nitrogen gas to evaporate the  $\text{CHCl}_3$ , resuspended in sterile water by probe sonication, and added to plates after allowing autoclaved media to cool to 55°C). Plates were incubated at 25°C or 37°C for 4–7 d. Invertase secretion was measured as described (Goldstein and Lampen, 1975; Bankaitis *et al.* 1989). The invertase secretion index of each sample was determined by dividing external invertase by total invertase.

## Routine Procedures

Lipid phosphorus was determined using the method of Ames and Dubin (1960). Protein was quantitated by the method of Lowry *et al.* (1951)



**Figure 2.** Phosphatidylcholine synthesis via the CDP-choline pathway. The CTY434 cells (*sec14*<sup>ts</sup> *cpt1::LEU2* *EPT1*) were transformed with high copy plasmids containing *CPT1*, *EPT1*, or the YEp352 vector. CTY160, CTY468, and CTY1-1A yeast contained only the YEp352 vector. [ $^{14}$ C]Choline (10,000 dpm/nmol, 10  $\mu\text{M}$ ) was added to 5 ml of mid-log phase yeast cells. Cells were grown at 25°C in yeast minimal media plus appropriate nutritional supplements. At 1 h cells were pelleted by centrifugation at 3000  $\times$  g for 5 min and washed with 5 ml of ice-cold water and lipids extracted as described in "Experimental Procedures." Phospholipids and CDP-choline pathway metabolites were separated by TLC. Results are the mean of  $n = 6$  experiments. SEs were  $<15\%$  for each mean.

## RESULTS

### Rationale

One of the current hypotheses for the ability of certain gene inactivations to allow for survival in the absence of the normally essential *SEC14* gene is that these mutations increase the Golgi DAG pool size (Kearns *et al.*, 1997). Part of the reasoning behind this hypothesis was the observation that inactivation of the yeast *CPT1* gene allowed for cell survival in the absence of the normally essential *SEC14* gene product (Cleves *et al.*, 1991). However, inconsistent with the DAG pool size hypothesis was the observation that inactivation of the yeast *EPT1* gene did not allow for bypass of *SEC14* function, even though both the *CPT1* and *EPT1* gene products directly consume DAG for the synthesis of PC, and PC/PE, respectively (Cleves *et al.*, 1991). To further explore the relationship between the two Kennedy pathways for the synthesis of PC and PE, and their interaction with *SEC14*-mediated vesicle trafficking events, we instituted an in-depth metabolic, enzymatic, and vesicle transport analysis of each of these pathways.

### In Vivo and In Vitro Cholinephosphotransferase Activities

We first pulse-labeled yeast containing an inactivated *CPT1* gene (*cpt1::LEU2*), but with an intact *EPT1* gene, with radio-



**Table 1.** Cholinephosphotransferase activity

Diacylglycerol substrate	Plasmid/gene	Cholinephosphotransferase activity (nmol min <sup>-1</sup> mg <sup>-1</sup> )
di16:1	YEp352/none	0.28 ± 0.02
	pRH150/ <i>CPT1</i>	13.01 ± 0.51
	pRH507/ <i>EPT1</i>	9.79 ± 0.45
di18:1	YEp352/none	0.92 ± 0.16
	pRH150/ <i>CPT1</i>	4.11 ± 0.22
	pRH507/ <i>EPT1</i>	17.42 ± 0.74
di8:0	YEp352/none	undetectable
	pRH150/ <i>CPT1</i>	0.20 ± 0.06
	pRH507/ <i>EPT1</i>	0.17 ± 0.01

*S. cerevisiae* strain CTY434 (*sec14<sup>ts</sup> cpt1::LEU2 EPT1*) was grown to log phase at 25°C in synthetic dextrose media containing appropriate nutritional supplements required for the maintenance of the high copy plasmid YEp352, YEp352 containing *CPT1* (pRH150), of YEp352 containing *EPT1* (pRH507). Cells were disrupted and microsomal membranes were isolated. Cholinephosphotransferase activities were determined using the mixed micelle assay described in "Experimental Procedures." Results are mean ± SE (n = 4).

labeled choline. This yeast strain synthesized PC at levels 60% of those expressing an intact *CPT1* gene (Figure 2), and overexpression of *EPT1* reconstituted PC biosynthetic levels to 100% those provided by *CPT1*. Disruption of the other two genes coding for enzymes within the Kennedy pathway for PC synthesis, *CK1I* and *PCT1*, reduced PC biosynthesis levels to 5 and 1% of wild-type levels, respectively. Analysis of the metabolites within the Kennedy pathway for PC synthesis were consistent with complete blocks at the choline kinase step for yeast containing an inactivated choline kinase gene (*cki1<sup>-</sup>*), an inactivated CTP:phosphocholine cytidyltransferase gene (*pct1::URA3*), and a partial block in yeast containing an inactivated cholinephosphotransferase gene (*cpt1::LEU2*). These results demonstrated that the partitioning of PC synthesis through the Kennedy pathway enzymes was not mutually exclusive. The Kennedy pathway enzymes could significantly overlap in substrate usage in vivo at the ultimate *CPT1*- and *EPT1*-encoded phosphotransferase step.

To ensure the high copy plasmid-borne *EPT1* and *CPT1* vectors were indeed altering cholinephosphotransferase activity levels, yeast cells were analyzed using an in vitro mixed micelle assay reconstitution system (Table 1) (Hjelmstad and Bell, 1991b; McMaster and Bell, 1994; Williams and McMaster, 1998). Because the yeast cells used in these studies contain an inactivated *CPT1* gene, the endogenous measurable cholinephosphotransferase activity was due solely to the remaining *EPT1*-encoded enzyme. Endogenous *EPT1*-encoded cholinephosphotransferase activity was determined to be 0.92 nmol min<sup>-1</sup> mg<sup>-1</sup> when di18:1 DAG was used as the phosphocholine acceptor substrate, 0.28 nmol min<sup>-1</sup> mg<sup>-1</sup> for di16:1 DAG, and no activity was detectable when the short-chain di8:0 DAG was provided as substrate. Overexpression of *EPT1* increased these activities 10–40-fold to 17.42, 9.79, and 0.17 nmol min<sup>-1</sup> mg<sup>-1</sup> for di18:1, di16:1, and di8:0 DAGs, respectively. As expected, overexpression of *CPT1* also increased cholinephosphotransferase


activity to 13.01 nmol min<sup>-1</sup> mg<sup>-1</sup> for di16:1 DAG, versus 4.11 nmol min<sup>-1</sup> mg<sup>-1</sup> for di18:1 DAG and 0.20 nmol min<sup>-1</sup> mg<sup>-1</sup> for di8:0 DAG.

### Phosphatidylcholine Synthesis and Vesicle Trafficking

The study of the essential *SEC14*-encoded PC/PI transfer protein has been facilitated by the isolation of a conditional temperature-sensitive *SEC14* allele, *sec14<sup>ts</sup>* (Cleves *et al.*, 1991). At the permissive temperature of 25°C cells containing the *sec14<sup>ts</sup>* allele possess normal *SEC14*-mediated PC/PI transfer activity and thus can transport vesicles from the Golgi and grow normally. Upon raising cell culture conditions to 37°C, a nonpermissive temperature for the *sec14<sup>ts</sup>* allele, cells can no longer catalyze the PC/PI transfer in vitro and in vivo cells cease Golgi-mediated vesicle transport and eventually die (Bankaitis *et al.*, 1990; Cleves *et al.*, 1991). It has been previously observed that mutations within the *cpt1* gene bypassed the requirement for a functional *SEC14* gene product and allowed *sec14<sup>ts</sup>* cells to grow at 37°C, but mutations in the *cpt1* gene did not restore secretory competence or cell viability (Cleves *et al.*, 1991).

Previous in vivo metabolic analysis of the partitioning of the Kennedy pathways revealed that *CPT1*-encoded activity synthesized the majority of PC and barely detectable levels of PE, whereas *EPT1*-encoded activity synthesized a small amount of PC and the bulk of Kennedy pathway-derived PE (McMaster and Bell, 1994). In addition, increased expression of *EPT1* did not affect its contribution toward the synthesis of PC (McMaster and Bell, 1994). In the current study, we were surprised by our observation that in the yeast strain used here, which contained an inactivated *CPT1* gene but intact *EPT1* gene, the level of PC synthesis was 60% that of wild-type, and overexpression of *EPT1* restored PC synthesis to 100% wild-type levels. These data imply that there are as yet uncharacterized cellular events that can alter the ability of *EPT1* to significantly contribute to the synthesis of PC. However, these same observations now provided an experimental system to examine how alterations in consumption of endogenous DAG by yeast enzymes affected *SEC14*-mediated vesicle transport processes and cell viability.

The yeast strain that contained the active *EPT1* gene and inactivated *CPT1* gene used in the metabolic labeling experiments described above also contained a conditional temperature-sensitive *sec14<sup>ts</sup>* allele. Normally, an inactivated *CPT1* gene (*cpt1::LEU2*) would be predicted to allow for a bypass of the essential requirement for *SEC14* and allow the yeast to survive and successfully transport vesicles from the Golgi apparatus at both the *sec14<sup>ts</sup>*-permissive temperature of 25°C and the *sec14<sup>ts</sup>*-nonpermissive temperature of 37°C (Cleves *et al.*, 1991). We tested whether disruption of the *CPT1* gene in the current strain, which resulted in the surprisingly high level of PC synthesis (to 60% of wild-type levels) due to the remaining *EPT1* gene, was still capable of bypassing the cellular requirement for a functional *SEC14* gene product (Figure 3A). The 40% decrease in Kennedy pathway-derived PC synthesis in the *EPT1 cpt1::LEU2* yeast strain was sufficient to allow for survival in the face of a nonfunctioning *SEC14* gene product. Upon overexpression of *EPT1* or *CPT1*, PC synthesis was restored to 100% wild-type levels, and these yeast cells could no longer survive at 37°C, indicating



**Figure 3.** EPT1 and di8:0 diacylglycerol affect *SEC14*-mediated cell growth. (A) CTY434 yeast (*sec14<sup>ts</sup> cpt1::LEU2 EPT1*) transformed with *CPT1* or *EPT1* in the high copy number YEp352 vector, or YPP649.7 (*sec7<sup>ts</sup>*), YPP649.13 (*sec13<sup>ts</sup>*), and YPP649.15 (*sec15<sup>ts</sup>*) transformed with YEp352 were grown overnight at 25°C in appropriate selective medium to ensure plasmid maintenance and diluted to identical cell number as determined spectrophotometrically by culture absorbance at 600 nm. Serial dilutions (1:10) were performed, and 1  $\mu$ l of each dilution was plated onto SC minus uracil plates. (B) The identical experiment except 1  $\mu$ l of each dilution was plated onto SC minus uracil plates containing 200  $\mu$ M di8:0 diacylglycerol. All plates were incubated for 4 d at 25°C or 7 d at 37°C. [*CPT1*] and [*EPT1*] indicate the presence of YEp352 plasmid-borne genes.

the reimposition of the requirement for a functional *SEC14* gene product.


To correlate the observed effects on cell growth with alterations in vesicle transport, the ability of each of the cells to secrete invertase was measured after cells were shifted to the *sec14<sup>ts</sup>*-nonpermissive temperature of 37°C. Cells containing the *sec14<sup>ts</sup>* mutation alone displayed a significant decrease in their ability to secrete invertase compared with wild-type yeast. In cells containing the *sec14<sup>ts</sup>* allele, inactivation of the first two enzymes of the Kennedy pathway for the synthesis of PC, choline kinase (*CK1I*) and CTP:phosphocholine cytidyltransferase (*PCT1*), resulted in an increase in invertase secretion to levels at or near those of wild-type cells (Figure 4). Interestingly, the ability to secrete invertase was only moderately increased in *sec14<sup>ts</sup>* cells containing an inactivated cholinephosphotransferase gene (*CPT1*). Overexpression of *EPT1* or *CPT1* in the *sec14<sup>ts</sup> cpt1::LEU2* cells decreased invertase secretion to near those observed for cells containing the *sec14<sup>ts</sup>* allele alone. Total invertase enzyme activities were not affected by ablation of Sec14p function compared with wild-type yeast, and the restoration of secretion competency through inactivation of the genes of the CDP-choline pathway did not significantly alter total invertase enzyme activity. Compared with wild-type yeast (100%), the *sec14<sup>ts</sup>* strain possessed total invertase activity of 96% wild-type, whereas the bypass suppressors, containing both the *sec14<sup>ts</sup>* mutation and disruptions of each of the genes of the

CDP-choline pathway, had invertase activities ranging from 65 to 103% those of wild-type yeast.

To sum, complete abolition of PC synthesis in cells grown at the nonpermissive temperature for the *sec14<sup>ts</sup>* allele resulted in invertase secretion at wild-type levels (3–4-fold above those observed in cells containing the *sec14<sup>ts</sup>* allele alone), whereas PC synthesis at 60% wild-type levels increased invertase secretion to 1.5–2-fold (compared with the *sec14<sup>ts</sup>* allele alone) but was sufficient to allow for life, whereas restoration of PC synthesis to 100% wild-type levels reimposed the requirement for functional *SEC14* on the cells. Hence, the rate of invertase secretion correlated directly with the rate to which PC synthesis was decreased. These results are consistent with the notion that the rate of endogenous DAG consumption was directly affecting the requirement for *SEC14*; however, lipid pathways downstream of DAG consumption or PC synthesis may also be impacting on *SEC14*-mediated events.

#### Effect of Di8:0 Diacylglycerol on Cell Growth and Lipid Metabolism

Di8:0 DAG is a synthetic lipid not produced in eukaryotic cells, but its increased solubility compared with long-chain DAGs has been exploited to allow for its use as a pharmacological tool to demonstrate DAG-specific regulatory and signaling events (Davis *et al.*, 1985; Kearns *et al.*, 1997). Di8:0



**Figure 4.** Invertase secretion indices. Yeast strains CTY182 (wild-type, *SEC14 CPT1 EPT1*), CTY1-1A (*sec14<sup>ts</sup> CPT1 EPT1*), CTY160 (*sec14-1<sup>ts</sup> ck1<sup>-</sup>*), CTY468 (*sec14-1<sup>ts</sup> pct1::URA3*), or CTY434 (*sec14<sup>ts</sup> cpt1::LEU2 EPT1*) transformed with the vector control YEpl352, or *CPT1* or *EPT1* in the high copy number YEpl352 vector, were grown to mid-log phase in YPD (2% glucose) medium at 25°C. Cells were pelleted (2000 × *g* for 1 min), washed twice with water, and resuspended in 5 ml of YPD containing 0.1% glucose. Cultures were subsequently grown at 37°C to impose the temperature-sensitive phenotype and invertase activities were determined as described in "Experimental Procedures." Results are expressed as the mean ± SE (*n* = 6), except for CTY160 and CTY468 (*n* = 3).

DAG was added to the medium of *sec14<sup>ts</sup> cpt1::LEU2* cells, which contained plasmid-borne *EPT1*, *CPT1*, or a vector control. The addition of di8:0 DAG rescued cells via a reproducible partial suppression of the *sec14<sup>ts</sup>* growth phenotype at 37°C in *sec14<sup>ts</sup> cpt1::LEU2* cells and this was independent of whether cells were overexpressing *CPT1* or *EPT1* (Figure 3B). The addition of di8:0 DAG did not rescue growth at the nonpermissive temperature for *sec7<sup>ts</sup>* and *sec13<sup>ts</sup>* yeast, which are defective in endoplasmic reticulum to Golgi transport, and *sec15<sup>ts</sup>*-containing cells, which are defective in secretion at the Golgi-to-plasma membrane step, implying the rescue of cell growth by di8:0 DAG was specific to Sec14p-mediated events. In addition, the lack of correlation between *CPT1* and *EPT1* expression and the ability of di8:0 DAG to alter *SEC14*-mediated events is consistent with our *in vitro* observation that di8:0 DAG was a poor substrate for these enzymes. The above-mentioned data indicate di8:0 DAG is likely not metabolized by either *CPT1*- or *EPT1*-derived activities, but if we are to effectively examine the role of DAG on *SEC14*-mediated vesicle transport events the effect of di8:0 DAG on DAG pool sizes and lipid metabolism parameters need to be measured.


The addition of 200 μM di8:0 DAG to early log phase yeast resulted in an accumulation of di8:0 DAG to 20–40 times those of endogenous long-chain DAG levels (Figure 5). Overexpression of *CPT1* or *EPT1* did not affect the levels of di8:0 DAG, indicating these enzymes were not effectively consuming di8:0 DAG, consistent with the *in vitro* substrate

specificity data and the di8:0 DAG cell growth assays (Table 1 and Figure 3). Although the combined results indicate di8:0 DAG was not effectively metabolized by yeast, and almost certainly not via *CPT1*- or *EPT1*-derived activities, the vast increase in intracellular di8:0 DAG levels prompted us to examine whether di8:0 DAG administration affected gross lipid metabolism. The incorporation of phosphorus 32 into yeast in the presence and absence of 200 μM di8:0 DAG was determined. Total net lipid synthesis was not affected by the addition of di8:0 DAG (Figure 6). Phospholipids within the lipid fraction were separated by two-dimensional TLC and the plates were exposed to x-ray film. The addition of di8:0 DAG did not affect the incorporation of phosphorus 32 into PC, PE, PI, phosphatidylserine, phosphatidic acid, CDP-diacylglycerol, phosphatidylglycerol, or cardiolipin. Importantly, we also noted that there was no conversion of the di8:0 DAG to di8:0 phosphatidic acid because there was no radiolabel associated with the mobility of this lipid in the two-dimensional TLC system used. We demonstrated that the lipid extraction protocol used in this study efficiently extracted the majority of di8:0 phosphatidic acid (our unpublished results). In addition, a visual analysis of the x-ray film did not reveal any uniquely labeled regions upon the addition of di8:0 DAG. Hence, the data are consistent with di8:0 DAG entering cells and dramatically increasing cellular DAG levels; however, di8:0 DAG did not appear to alter phospholipid metabolic pathways, or to be converted to di8:0 phosphatidic acid.

## DISCUSSION

The metabolic partitioning of the Kennedy pathways for the synthesis of PC and PE has been controversial. *In vitro* analysis of purified enzymes and cloned gene products has demonstrated that several enzymes of the Kennedy pathway possess the capacity to use both ethanolamine and choline pathway components. Thus, it has been hypothesized that the two metabolic pathways may contain the same enzyme components, or that the dual substrate specificity of some of the enzymes may at a minimum result in overlap between enzymes that possess substrate specificity and those that are promiscuous in their use of substrates. Most notable among these *in vitro* results are the ability of some mammalian kinases to phosphorylate both choline and ethanolamine (Porter and Kent, 1990; Kent, 1995), and the ability of some phosphotransferases to use CDP-choline and CDP-ethanolamine for the synthesis of PC and PE (Hjelmstad *et al.*, 1994; Henneberry and McMaster, 1999; Henneberry *et al.*, 2000). Recent *in vivo* observations have resulted in the conclusion that the ability of the CDP-ethanolamine pathway enzymes to use CDP-choline is restricted to the *in vitro* situation, because radiolabeling experiments in yeast carrying inactivated genes for various enzymes within the Kennedy pathways revealed that there was strict metabolic pathway partitioning (McGee *et al.*, 1994; McMaster and Bell, 1994; Kim *et al.*, 1999). However, this observation was recently challenged by the cloning of the human complement of choline-phosphotransferase and ethanolaminophosphotransferase enzymes. The human *CPT1* product specifically used CDP-choline as its phosphobase donor *in vitro* and metabolic experiments demonstrated that hCPT1 reconstituted only PC synthesis *in vivo* in yeast devoid of their endogenous






**Figure 5.** Effect of exogenous di8:0 diacylglycerol administration on diacylglycerol pool sizes. CTY434 cells  $\pm$  plasmids were grown overnight at 25°C in synthetic dextrose media containing the appropriate nutrients. Optical densities were measured at 600 nm and each strain was diluted to  $A_{600}$  of 0.150. Cells were grown for 1 h at 25°C and the medium was subsequently supplemented with di8:0 DAG to a final concentration of 200  $\mu$ M. Five-milliliter aliquots were

cholinephosphotransferase and ethanolaminephosphotransferase activities (Henneberry *et al.*, 2000). However, the human CEPT1 product could use both CDP-choline and CDP-ethanolamine in vitro and was capable of reconstituting the synthesis of both PC and PE in yeast in vivo (Henneberry and McMaster, 1999). Our current study supports and extends this observation. We have found a yeast strain whereby endogenous yeast *EPT1*-derived cholinephosphotransferase activity can contribute to 60% of net Kennedy pathway-derived PC synthesis and overexpression of *EPT1* reconstituted PC synthesis to wild-type levels. The precise mechanisms that allow for the overlap in substrate specificity by *EPT1* remain to be identified, but it is clear that the Kennedy pathways are not strictly partitioned and can significantly overlap at the ultimate step in the synthesis of PC and PE.

*SEC14* codes for an essential yeast PC/PI transfer protein. Previous experimentation had demonstrated that inactivation of the *CPT1* gene, and the other enzymes within the Kennedy pathway for PC synthesis, allowed cells to survive in the absence of a functional *SEC14* gene product, but inactivation of the *EK11* and *EPT1* genes for the synthesis of PE did not bypass the cellular requirement for *SEC14* (Cleves *et al.*, 1991; Kim *et al.*, 1999). The current paradigm whereby *SEC14* serves to mediate Golgi DAG levels to maintain secretory competence was consistent with the inactivation of *CPT1*, but not *EPT1*, to bypass the essentiality of *SEC14*, because both *CPT1* and *EPT1* gene products directly consume DAG. However, the present study demonstrated that the rate of endogenous PC synthesis, and hence DAG consumption, directly correlated with the level of *SEC14*-dependent invertase secretion. Thus, these data predict that the rate of endogenous DAG consumption by *EPT1* is normally sufficiently low so as not contribute significantly to DAG metabolism. Our recent cloning of the human *CPT1* and *CEPT1* gene products allowed us to test the role of each of these gene products in their ability to interact with the *SEC14* secretory apparatus. We observed that expression of human *CEPT1*, but not *CPT1*, was able to mimic endogenous yeast *CPT1* and prevent cell growth in the absence of a functional *SEC14* gene product in the same *sec14<sup>ts</sup> cpt1<sup>-</sup>* yeast used in the current study (Henneberry *et al.*, 2000). We also noted that expression of human *CPT1* restored PC synthesis to levels 70% that provided by expression of human *CEPT1*. Thus, a positive correlation exists between endogenous DAG consumption and restoration of *SEC14*-dependent vesicle trafficking to levels required for cell viability.

Consistent with the variations in endogenous DAG consumption affecting *SEC14*-mediated cell growth and secretory capacity was our demonstration of the ability of exogenous di8:0 DAG to rescue *sec14<sup>ts</sup>*-mediated cell death. This observation was complemented by the first assessment of

removed at the indicated time points and diacylglycerols were extracted and quantified as described in "Experimental Procedures." (A) CTY434 cells grown without di8:0 DAG supplementation. (B) CTY434 cells grown with di8:0 DAG supplemented to 200  $\mu$ M di8:0 DAG. (C) CTY434 cells containing high copy plasmids carrying the *CPT1* or *EPT1* genes supplemented to 200  $\mu$ M di8:0 DAG for 4 h. Results are the mean of  $n = 4$  experiments. SEs were  $<15\%$  for each mean.



**Figure 6.** Effect of exogenous di8:0 diacylglycerol administration on phospholipid synthesis. Inorganic  $^{32}$ P phosphorus (2.5 mCi) was added to 20 ml of mid-log phase CTY434 cells grown at 25°C in yeast minimal media plus appropriate nutritional supplements. At 4, 12, and 24 h a 5-ml aliquot was removed and centrifuged at  $3000 \times g$  for 5 min to pellet cells. Cells were washed twice with 5 ml

the effects of di8:0 DAG on DAG pool sizes and lipid metabolism in yeast. Di8:0 DAG entered yeast cells and accumulated to levels 20–40-fold higher than endogenous long-chain DAG. In addition, di8:0 DAG did not alter the rate of synthesis of PC, PE, PI, phosphatidylserine, phosphatidic acid (PA), CDP-DAG, phosphatidylglycerol, or cardiolipin (Patton-Vogt *et al.*, 1997; Siddhanta and Shields, 1998). However, it should be noted that the shift in temperature from 25°C to 37°C did not affect the cellular long-chain DAG pool size. How this observation fits with the DAG pool size paradigm has yet to be effectively reconciled, except by proposing a Golgi-specific DAG pool that does not significantly contribute to total cellular DAG levels.

The hypothesis that *SEC14* impacts on the regulation of Golgi DAG pool sizes is consistent with the observation that PC-bound *SEC14* protein inhibits PC synthesis by inhibition of CTP:phosphocholine cytidyltransferase (*PCT1*), the rate-limiting step in PC synthesis (Skinner *et al.*, 1995). Inhibition of *Pct1p* activity decreases the availability of CDP-choline for use by *Cpt1p* and *Ept1p* for PC synthesis and DAG consumption. Inactivation of the yeast phospholipase D gene (*SPO14/PLD1*) (Waksman *et al.*, 1996; Rudge and Engebrecht, 1999; Li *et al.*, 2000), in each of the *sec14*<sup>-</sup> bypass mutants reimposed the requirement for a functional *SEC14* gene product (Sreenivas *et al.*, 1998; Xie *et al.*, 1998). If the DAG consumption hypothesis is correct, then the PA generated by *SPO14*-derived activity would be predicted to be metabolized to DAG, however, the PA phosphatase genes required to directly test this hypothesis have yet to be identified in yeast.

An interesting observation during the *SPO14* inactivation analysis revolved around the *SAC1* gene. The *SAC1* gene codes for a PI-4-P phosphatase (Guo *et al.*, 1999; Hughes *et al.*, 2000) and was one of the original *sec14*<sup>-</sup> bypass suppressors. Inactivation of *SAC1* resulted in a fivefold increase in PI-4-P levels (Hama *et al.*, 1999; Rivas *et al.*, 1999; Stock *et al.*, 1999) and hence it was proposed that PI-4-P levels directly correlated with the ability of *SEC14* to function during vesicle trafficking (Hama *et al.*, 1999; Stock *et al.*, 1999). However, the inactivation of *SPO14* in the *sec14*<sup>ts</sup> *sac1* yeast reversed the bypass effect of *sac1* and resulted in decreased secretion and eventual cell death, however PI-4-P levels remained high (Rivas *et al.*, 1999). Thus, the role of PI-4-P in mediating *SEC14* function is still unclear. In one of these studies it was noted that *sac1* mutants displayed a dramatic increase in flux through the CDP-choline pathway for PC synthesis (Rivas *et al.*, 1999). Inactivation of *SPO14* in *sac1*<sup>-</sup> yeast restored PC synthesis to normal rates, indicating that *SPO14*-generated products directly affected PC synthesis. The most likely explanation for these results are that the PA generated by phospholipase D hydrolysis is normally con-

of ice-cold water and lipids extracted as described in "Experimental Procedures." Phospholipids were separated by two-dimensional TLC with  $\text{CHCl}_3/\text{CH}_2\text{COCH}_3/\text{CH}_3\text{OH}/\text{CH}_3\text{COOH}/\text{H}_2\text{O}$  (60:24:12:12:6, vol/vol) in the first dimension and  $\text{CHCl}_3/\text{CH}_3\text{OH}/\text{CH}_3\text{COOH}/\text{H}_2\text{O}$  (50:37.5:3.5:2, vol/vol) in the second dimension. (A) Incorporation of  $^{32}$ P phosphorus into total phospholipid. (B) Incorporation of  $^{32}$ P phosphorus into individual lipid classes. (C) Incorporation of  $^{32}$ P phosphorus into individual lipid classes in the presence of 200  $\mu\text{M}$  di8:0 DAG. Results are the mean of  $n = 4$  experiments. SEs were  $<15\%$  for each mean.



verted to DAG for consumption by *CPT1*- and *EPT1*-derived phosphotransferase activities.

The challenge in analyzing alterations in lipid metabolism in the face of *SEC14* dysfunction, and the accompanying bypass suppressors, is addressing which lipids play a direct role in modulating protein secretion and cell growth. The data presented in this study include correlations of endogenous DAG consumption with invertase secretion indices and cell viability, and exogenous DAG administration affecting *SEC14*-mediated cell death. In addition, exogenous DAG did not affect the metabolism of any phospholipid tested, nor was it converted to di8:0 phosphatidic acid, implying DAG itself was likely the mediator allowing for *SEC14*-dependent alterations in protein secretion and cell growth. The most obvious steps in the elucidation of the precise mechanisms of *SEC14*-mediated protein secretion will be an assessment of whether the lipids themselves promote vesicle fusion (Ruiz-Arguello *et al.*, 1996), or whether there are protein targets for lipid activation or inhibition, and an assessment of how these impact on *SEC14*-mediated vesicle trafficking.

## ACKNOWLEDGMENTS

We thank Harold Cook and David Byers (Dalhousie University, K. Halifax, NS, Canada) for helpful comments during the course of these studies. This work was supported by a Canadian Institutes of Health Research Doctoral Award (A.L.H.), CIHR Scholarship and Operating Awards (C.R.M.), CIHR Scientist and Operating Awards (N.D.R.), and a CIHR Group Grant (N.D.R. and C.R.M.).

## REFERENCES

- Achleitner, G., Zweytick, D., Trotter, P.J., Voelker, D.R., and Daum, G. (1995). Synthesis and intracellular transport of aminoglycero-phospholipids in permeabilized cells of the yeast, *Saccharomyces cerevisiae*. *J. Biol. Chem.* 270, 29836–29842.
- Aitken, J.F., van Heusden, G.P.H., Temkin, M., and Dowhan, W. (1990). The gene encoding the phosphatidylinositol transfer protein is essential for cell growth. *J. Biol. Chem.* 265, 4711–4717.
- Ames, B.N., and Dubin, D.T. (1960). The role of polyamines in the neutralization of bacteriophage deoxyribonucleic acid. *J. Biol. Chem.* 235, 769–775.
- Bankaitis, V.A., Aitken, J.F., Cleves, A.E., and Dowhan, W. (1990). An essential role for a phospholipid transfer protein in yeast Golgi function. *Nature* 347, 561–562.
- Bankaitis, V.A., Malehorn, D.E., Emr, S.D., and Greene, R. (1989). The *Saccharomyces cerevisiae* *SEC14* gene encodes a cytosolic factor that is required for transport of secretory proteins from the yeast Golgi complex. *J. Cell Biol.* 108, 1271–1281.
- Clancey, C.J., Chang, S-C., and Dowhan, W. (1993). Cloning of a gene (*PSD1*) encoding phosphatidylserine decarboxylase from *Saccharomyces cerevisiae* by complementation of an *Escherichia coli* mutant. *J. Biol. Chem.* 268, 24580–24590.
- Cleves, A.E., McGee, T.P., Whitters, E.A., Champion, K.M., Aitken, J.R., Dowhan, W., Goebel, M., and Bankaitis, V.A. (1991). Mutations in the CDP-choline pathway for phospholipid biosynthesis bypass the requirement for an essential phospholipid transfer protein. *Cell* 64, 789–800.
- Cui, Z., Vance, J.E., Chen, M.H., Voelker, D.E., and Vance, D.E. (1993). Cloning and expression of a novel phosphatidylethanolamine N-methyltransferase. A specific biochemical and cytological marker for a unique membrane fraction in rat liver. *J. Biol. Chem.* 268, 16655–16663.
- Davis, R.J., Ganong, B.R., Bell, R.M., and Czech, M.P. (1985). *sn*-1,2-Dioctanoylglycerol. A cell-permeable diacylglycerol that mimics phorbol diester action on the epidermal growth factor receptor and mitogenesis. *J. Biol. Chem.* 260, 1562–1566.
- Goldstein, A., and Lampen, J.L. (1975).  $\beta$ -D-Fructofuranoside fructohydrolase from yeast. *Methods Enzymol.* 42, 504–511.
- Guo, S., Stolz, L.E., Lemrow, S.M., and York, J.D. (1999). *SAC1*-like domains of yeast *SAC1*, *INP52*, and *INP53* and of human synaptotagmin encode polyphosphoinositide phosphatases. *J. Biol. Chem.* 274, 12990–12995.
- Hama, H., Schnieder, E.A., Thorner, J., Takemoto, J.Y., and DeWald, D.B. (1999). Direct involvement of phosphatidylinositol 4-phosphate in secretion in the yeast *Saccharomyces cerevisiae*. *J. Biol. Chem.* 274, 34294–34300.
- Henneberry, A.L., and McMaster, C.R. (1999). Cloning and expression of a human choline/ethanolaminephosphotransferase: synthesis of phosphatidylcholine and phosphatidylethanolamine. *Biochem. J.* 339, 291–298.
- Henneberry, A.L., Wistowe, G., and McMaster, C.R. (2000). Cloning, genomic organization, and biochemical characterization of a human cholinephosphotransferase. *J. Biol. Chem.* 275, 29808–29815.
- Hjelmstad, R.H., and Bell, R.M. (1990). The *sn*-1,2-diacylglycerol cholinephosphotransferase of *Saccharomyces cerevisiae*. Nucleotide sequence, transcriptional mapping, and gene product analysis of the *CPT1* gene. *J. Biol. Chem.* 265, 1755–1764.
- Hjelmstad, R.H., and Bell, R.M. (1991a). *sn*-1,2-Diacylglycerol choline- and ethanolaminephosphotransferases in *Saccharomyces cerevisiae*. Mixed micellar analysis of the *CPT1* and *EPT1* gene products. *J. Biol. Chem.* 266, 4357–4365.
- Hjelmstad, R.H., and Bell, R.M. (1991b). *sn*-1,2-Diacylglycerol choline- and ethanolaminephosphotransferases in *Saccharomyces cerevisiae*. Nucleotide sequence of the *EPT1* gene and comparison of the *CPT1* and *EPT1* gene product. *J. Biol. Chem.* 266, 5094–5103.
- Hjelmstad, R.H., Morash, S.A., McMaster, C.R., and Bell, R.M. (1994). Chimeric enzymes. structure-function analysis of segments of *sn*-1,2- diacylglycerol choline- and ethanolaminephosphotransferases. *J. Biol. Chem.* 269, 20995–21002.
- Hughes, W.E., Woscholski, R., Cooke, F.T., Patrick, R.S., Dove, S.K., McDonald, N.Q., and Parker, P.J. (2000). *SAC1* encodes a regulated lipid phosphoinositide phosphatase, defects in which can be suppressed by the homologous *Inp52p* and *Inp53p* phosphatases. *J. Biol. Chem.* 275, 801–808.
- Kaiser, C., Michaelis, S., and Mitchell, A. (1994). *Methods in Yeast Genetics*, Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
- Kearns, B.G., Alb, J.G., and Bankaitis, V.A. (1998). Phosphatidylinositol transfer proteins: the long and winding road to physiological function. *Trends Cell Biol.* 8, 276–282.
- Kearns, B.G., McGee, T.P., Mayinger, P., Gedvilaite, A., Phillips, S.E., Kagiwada, S., and Bankaitis, V.A. (1997). Essential role for diacylglycerol in protein transport from the yeast Golgi complex. *Nature* 387, 101–105.
- Kent, C. (1995). Eukaryotic phospholipid biosynthesis. *Annu. Rev. Biochem.* 64, 315–343.
- Kim, K., Kim, K-H., Storey, M.K., Voelker, D.R., and Carman, G.M. (1999). Isolation and characterization of the *Saccharomyces cerevisiae* *EKII* gene encoding ethanolamine kinase. *J. Biol. Chem.* 274, 14857–14866.

- Kodaki, T., and Yamashita, S. (1987). Yeast phosphatidylethanolamine methylation pathway. Cloning and characterization of two distinct methyltransferase genes. *J. Biol. Chem.* 262, 15428–15435.
- Li, X., Routt, S.M., Xie, Z., Cui, X., Fang, M., Kearns, M.A., Bard, M., Kirsch, D.R., and Bankaitis, V.A. (2000). Identification of a novel family of nonclassic yeast phosphatidylinositol transfer proteins whose function modulates phospholipase D activity and Sec14p-dependent cell growth. *Mol. Biol. Cell* 11, 1989–2005.
- Lowry, O.H., Rosebrough, N.J., Farr, A.L., and Randall, R.J. (1951). Protein measurement with the Folin phenol reagent. *J. Biol. Chem.* 193, 265–275.
- McGee, T.P., Skinner, H.B., and Bankaitis, V.A. (1994). Functional redundancy of the CDP-ethanolamine and CDP-choline pathway enzymes in phospholipid biosynthesis: ethanolamine-dependent effects on steady-state membrane phospholipid composition in *Saccharomyces cerevisiae*. *J. Bacteriol.* 176, 6861–6868.
- McMaster, C.R., and Bell, R.M. (1994). Phosphatidylcholine biosynthesis in *Saccharomyces cerevisiae*. Regulatory insights from studies employing null and chimeric *sn*-1,2-diacylglycerol choline- and ethanolaminophosphotransferases. *J. Biol. Chem.* 269, 28010–28016.
- McMaster, C.R., and Bell, R.M. (1997a). CDP-choline: 1,2-diacylglycerol cholinephosphotransferase. *Biochim. Biophys. Acta* 1348, 100–110.
- McMaster, C.R., and Bell, R.M. (1997b). CDP-ethanolamine: 1,2-diacylglycerol ethanolaminophosphotransferase. *Biochim. Biophys. Acta* 1348, 117–123.
- Paltauf, F., Kohlwein, S.D., and Henry, S.A. (1992). The Molecular and Cellular Biology of the Yeast *Saccharomyces*, ed. E.W. Jones, J.R. Pringle, and J.R. Broach, Plainview, NY: Cold Spring Harbor Laboratory Press, 415–500.
- Patton-Vogt, J.L., Griac, P., Sreevinas, A., Bruno, V., Dowd, S., Swede, M.J., and Henry, S.A. (1997). Role of the yeast phosphatidylinositol/phosphatidylcholine transfer protein (Sec14p) in phosphatidylcholine turnover and *INO1* regulation. *J. Biol. Chem.* 272, 20873–20883.
- Phillips, S.E., *et al.* (1999). Yeast Sec14p deficient in phosphatidylinositol transfer activity is functional in vivo. *Mol. Cell* 4, 187–197.
- Porter, T.J., and Kent, C. (1990). Purification and characterization of choline/ethanolamine kinase from rat liver. *J. Biol. Chem.* 265, 414–422.
- Preiss, J., Loomis, C.R., Bishop, W.R., Stein, R., Niedel, J.E., and Bell, R.M. (1986). Quantitative measurement of *sn*-1,2-diacylglycerols present in platelets, hepatocytes, and *ras*- and *sis*-transformed normal rat kidney cells. *J. Biol. Chem.* 261, 8597–8600.
- Rivas, M.P., Kearns, B.G., Guo, S., Xie, Z., Sekar, C., Hosaka, K., Kagiwada, S., York, J.D., and Bankaitis, V.A. (1999). Pleiotropic alterations in lipid metabolism in yeast *sac1* mutants: relationship to “bypass Sec14p” and inositol auxotrophy. *Mol. Biol. Cell* 10, 2235–2250.
- Rudge, S.A., and Engebrecht, J. (1999). Regulation and function of PLDs in yeast. *Biochim. Biophys. Acta* 1439, 167–174.
- Ruiz-Arguello, M.B., Basanez, G., Goni, F.M., and Alonso, A. (1996). Different effects of enzyme-generated ceramides and diacylglycerols in phospholipid membrane fusion and leakage. *J. Biol. Chem.* 271, 26616–26621.
- Siddhanta, A., and Shields, D. (1998). Secretory vesicle budding from the trans-Golgi network is mediated by phosphatidic acid levels. *J. Biol. Chem.* 273, 17995–17998.
- Skinner, H.B., McGee, T.P., McMaster, C.R., Fry, M.R., Bell, R.M., and Bankaitis, V.A. (1995). The *Saccharomyces cerevisiae* phosphatidylinositol-transfer protein effects a ligand-dependent inhibition of choline-phosphate cytidyltransferase activity. *Proc. Natl. Acad. Sci. USA* 92, 112–116.
- Sreenivas, A., Patton-Vogt, J.L., Bruno, V., Griac, P., and Henry, S.A. (1998). A role for phospholipase D (Pld1p) in growth, secretion, and regulation of membrane lipid synthesis in yeast. *J. Biol. Chem.* 273, 16635–16638.
- Stock, S.D., Hama, H., DeWald, D.B., and Takemoto, J.Y. (1999). *SEC14*-dependent secretion in *Saccharomyces cerevisiae*. Nondependence on sphingolipid synthesis-coupled diacylglycerol production. *J. Biol. Chem.* 274, 12979–12983.
- Trotter, P.J., Pedretti, J., and Voelker, D.R. (1993). Phosphatidylserine decarboxylase from *Saccharomyces cerevisiae*. Isolation of mutants, cloning of the gene, and creation of a null allele. *J. Biol. Chem.* 268, 21416–21424.
- Trotter, P.J., and Voelker, D.R. (1995). Identification of a non-mitochondrial phosphatidylserine decarboxylase activity (*PSD2*) in the yeast *Saccharomyces cerevisiae*. *J. Biol. Chem.* 270, 6062–6070.
- Vance, J.E. (1991). Newly made phosphatidylserine and phosphatidylethanolamine are preferentially translocated between rat liver mitochondria and endoplasmic reticulum. *J. Biol. Chem.* 266, 89–97.
- Vance, D.E. (1996). *Biochemistry of Lipids, Lipoproteins and Membranes*, ed. D.E. Vance and J.E. Vance, Amsterdam: Elsevier Scientific, 153–182.
- Waksman, M., Eli, Y., Liscovitch, M., and Gerst, J.E. (1996). Identification and characterization of a gene encoding phospholipase D activity in yeast. *J. Biol. Chem.* 271, 2361–2364.
- Weiss, S.B., Smith, S.W., and Kennedy, E.P. (1958). The enzymatic formation of lecithin from cytidine diphosphate choline and D-1,2-diglyceride. *J. Biol. Chem.* 233, 53–64.
- White, D.A. (1973). *Form and Function of Phospholipids*, ed. G.B. Ansell, J.N. Hawthorne, and R.M.C. Dawson, Amsterdam, Elsevier Scientific, 441–482.
- Williams, J.G., and McMaster, C.R. (1998). Scanning alanine mutagenesis of the CDP-alcohol phosphotransferase motif of *Saccharomyces cerevisiae* cholinephosphotransferase. *J. Biol. Chem.* 273, 13482–13487.
- Xie, Z., Fang, M., Rivas, M.P., Faulkner, A.J., Sternweis, P.C., Engebrecht, J., and Bankaitis, V.A. (1998). Phospholipase D activity is required for suppression of yeast phosphatidylinositol transfer protein defects. *Proc. Natl. Acad. Sci. USA* 95, 12346–12351.